Fabry and Cardiomyopathy (FaCard)
NCT01429597 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2021-04-09
Summary
Primary objective and endpoint is the analysis of the long-term course of lyso-Gb3 and its clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients.
Conditions
- Cerebrovascular Accident
- Stroke, Acute
- Cerebral Stroke
Sponsors & Collaborators
-
CENTOGENE GmbH Rostock
lead INDUSTRY
Principal Investigators
-
Arndt Rolfs, Prof. Dr. · CENTOGENE GmbH Rostock
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-07-01
- Primary Completion
- 2019-12-01
- Completion
- 2019-12-01
Countries
- Germany
Study Locations
More Related Trials
-
Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients
NCT00414583 ·Status: COMPLETED
-
A Study of Patients With Fabry Disease (US Specific)
NCT06906367 ·Status: RECRUITING
-
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy
NCT03230149 ·Status: COMPLETED
-
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease
NCT05046379 ·Status: COMPLETED
-
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
NCT05698901 ·Status: RECRUITING
-
T1 Mapping in Fabry Disease
NCT05923788 ·Status: RECRUITING ·Phase: NA
-
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
NCT03737214 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
NCT04049760 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
NCT02489344 ·Status: COMPLETED ·Phase: PHASE2
-
German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.
NCT03135197 ·Status: COMPLETED
-
Fabry Disease Registry & Pregnancy Sub-registry
NCT00196742 ·Status: RECRUITING
-
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
NCT02194985 ·Status: COMPLETED ·Phase: PHASE3
-
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
NCT00413595 ·Status: COMPLETED
-
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
NCT04143958 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
NCT00074958 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease
NCT00140621 ·Status: COMPLETED ·Phase: PHASE4
-
French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat
NCT04602364 ·Status: COMPLETED
-
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
NCT00106912 ·Status: COMPLETED
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT06904261 ·Status: RECRUITING ·Phase: PHASE3
-
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
NCT00864851 ·Status: COMPLETED ·Phase: PHASE3
-
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
NCT06065605 ·Status: UNKNOWN
-
Ten Year Follow-up in FSHD: the FOCUS 3 Study
NCT06911190 ·Status: RECRUITING
-
Long-Term Follow-up of Subjects Who Were Treated With ST-920
NCT05039866 ·Status: ENROLLING_BY_INVITATION
-
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00081497 ·Status: COMPLETED ·Phase: PHASE4